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Abstract 
Background: Allergen‑specific immunotherapy (AIT) is the only treatment able to change the natural course of 
allergic diseases. We aimed at investigating the clinical efficacy of SLITOR (Serbian registered vaccine for sublingual 
allergen specific immunotherapy).
Methods: 7–18 years old children with allergic asthma and rhinitis were enrolled and addressed to the active (AIT 
plus pharmacological treatment) or control (standard pharmacological treatment only) group. Clinical and medica‑
tions scores, lung function and exhaled FeNO were measured at baseline and at every follow‑up.
Results: There was a significant improvement in both nasal and asthma symptom scores as well as in medication 
score in SLIT group. SLIT showed an important influence on lung function and airway inflammation.
Conclusions: Our data showed that SLITOR was effective not only in terms of patient reported outcomes but an 
improvement of pulmonary function and decrease of lower airway inflammation were also observed.
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Background
Asthma is a chronic disease of the airways characterized 
by inflammation and bronchial remodeling. With a global 
prevalence of 9.4% in 6–7 years old patients and 12.6% in 
13–14 years old patients asthma is one of the most com-
mon chronic diseases in childhood age [1, 2]. The growing 
medical and social burden of asthma is often described 
as the ‘allergy epidemic’ [3]. Allergen-specific immuno-
therapy (AIT) holds a great promise in the management 
of allergic conditions, as it is the only treatment able 
to change the natural course of respiratory allergic dis-
eases [4]. The disease modifying effect assumes a special 
relevance in the pediatric age, when the plasticity of the 
immune system is maximal, and the preventive effects can 
be reasonably expected [5]. During the last three decades 
sublingual immunotherapy (SLIT) impressively devel-
oped, offering patients an excellent safety and acceptance 
profile, and a similar efficacy profile when compared with 
subcutaneous immunotherapy (SCIT) [6, 7]. Although 
the clinical efficacy of SLIT in children with asthma and 
allergic rhinitis has been proved in many double blind pla-
cebo control randomized clinical trials (DBPC-RCT) and 
meta-analysis, there is a lack of objective measures related 
to SLIT efficacy, besides patients reported outcomes [8]. 
Most of the published studies have considered clinical 
scores as the main efficacy parameter, whilst immunologi-
cal and inflammatory parameters have been only occa-
sionally investigated [9]. Recent research has been more 
focused on identifying objective biomarkers. They can 
be helpful in early detection of subjects at risk of asthma 
development as well as in asthma management, from the 
diagnosis to follow-up, and in treatment tailoring [10]. 
Up to now several immunological changes related to AIT 
Open Access
Clinical and Molecular Allergy
*Correspondence:  ma.caminati@gmail.com 
2 Allergy Unit and Asthma Center, Verona University and General Hospital, 
Piazzale Stefani 1, 37126 Verona, Italy
Full list of author information is available at the end of the article
Page 2 of 7Djuric‑Filipovic et al. Clin Mol Allergy  (2017) 15:7 
mechanisms of action have been described: allergen spe-
cific IgE, allergen-specific blocking IgG4, eosinophil reac-
tivity, FeNO, eosinophil cationic protein (ECP), allergen 
specific suppressor T cells as well as the deviation of type 
2 T helper cells (Th2) response in favor of Th1 response 
[11, 12]. FeNO measurement is currently the only vali-
dated non-invasive method for assessing asthma-related 
eosinophilic inflammation in clinical practice. Literature 
data has already shown that treatment with inhaled or 
oral corticosteroids as well as with biological treatment 
such as monoclonal humanized anti-IgE antibody is able 
to decrease the level of FeNO in children with asthma and 
allergic rhinitis [13].
The aims of our study were:
1. To prove the clinical efficacy of SLITOR (registered 
vaccine for sublingual allergen specific immunother-
apy) produced by the local Serbian Institute for virol-
ogy, vaccines and serum (Torlak, Belgrade, Serbia) in 
terms of improvement of clinical symptoms (nasal 
and bronchial symptoms) and decrease of medica-
tion usage.
2. To show the impact of SLIT on the improvement of 
pulmonary function
3. To investigate the influence of SLIT on eosinophil 
airway inflammation—measured with the concentra-
tion of exhaled NO (FeNO)
Methods
Our study was a real life controlled observational study. 
The study was conducted in the Children’s Hospital 
for Lung Diseases and Tuberculosis, Medical Centre 
“Dr Dragiša Mišović”, Belgrade, Serbia. The protocol 
was approved by the Ethical Committee of the hospi-
tal. Informed consent was obtained from all parents 
or caregivers of the participants. The active group was 
addressed to SLIT plus standard pharmacotherapy, 
whereas the control group undertook standard pharma-
cological treatment only.
Patients were considered eligible for SLIT according 
to the following factors: diagnosis of allergic rhinitis, 
diagnosis of asthma under control with standard phar-
macological treatment (without acute exacerbation in 
the last 6  months, without systemic corticosteroids in 
the last 6 months, without hospitalisation due to acute 
asthma attacks in the last 6 months, FEV1 ≥80%), posi-
tive skin prick tests with inhaled allergens, positive 
in vitro tests (CAP-RAST immunoassay, minimum IgE 
class III), age range between 7 and 18 years old. Hyper-
sensitivity to any of the vaccines components, pres-
ence or suspect of malignancies, autoimmune systemic 
diseases as well as immunodeficiency were considered 
exclusion criteria.
Skin prick tests (SPT) were performed according to 
published guidelines with a standard battery of glyceri-
nated extracts (Institute of Virology, Vaccines and Sera 
TORLAK, Belgrade, Serbia). The following allergens were 
tested: house dust, dust mite (Dermatophagoides spp.), 
cockroach, mold, animal dander, pollens (tree, grass and 
weed). Histamine and saline were used as positive and 
negative controls, respectively. A drop of each allergen 
extract was placed on the volar surface of the forearm 
and was penetrated with a separate lancet. After 15 min, 
the wheal reaction was measured as the mean of the 
longest diameter and the diameter perpendicular to it. 
Reactions (mean wheal diameter ≥3  mm) were consid-
ered positive [17]. Serum specific IgE to allergens extract 
were assayed with an automated immuno-fluorimetric 
method (ImmunoCAP 100; Phadia, Upsalla, Sweden). 
The results were expressed as CAP scores from class 0–6, 
according to the manufacture’s instruction, (≥class 3 was 
accepted as relevant).
SLITOR (registered vaccine for sublingual allergen 
specific immunotherapy) produced by the local Serbian 
Institute for virology, vaccines and serum Torlak, Bel-
grade, Serbia was used in the study. The allergen extracts 
were used for the preparation of sublingual-swallow 
“vaccines” in phosphate-buffered saline with 50% glyc-
erol. Quality of allergen extract was tested with sodium 
dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blot technique (Fig.  1). The 
potency of the solution was expressed as protein nitrogen 
unit (PNU)/ml and prepared in three strengths: 16, 125 
and 1000 PNU/ml.
Fig. 1 Pre‑treatment SDS‑PAGE analysis of Dermatophagoides ptero-
nyssinus extract and IgE‑binding profiles class 6 from six sIgE positive 
patients from SLIT group. SDS‑PAGE sodium dodecyl sulfate–poly‑
acrylamide gel electrophoresis, D. pt Dermatophagoides pteronys-
sinus, Ab antibody, sIgE specific immunoglobulin E, SLIT sublingual 
immunotherapy
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According to manufacturer’s recommendations, in the 
build-up phase (45 days), patients received increasing doses 
of the extract, starting with one drop of 16  PNU/ml and 
increasing to 15 drops in 15 days. Daily dose was taken sub-
lingually, applied on a sugar cube in the morning, half an 
hour before breakfast. This process was repeated also for 
the 125 and 1000  PNU/ml. Finally, patient was switched 
to maintenance phase regimen, using 15 drops of the 1000 
PNU/ml twice a week for the following 24 months. Aller-
gen proteins concentration in maintenance therapy was 
equivalent to 19.9 μg/ml i.e. 0.995 μg of allergen proteins in 
one drop of extract. Calculated mean cumulative monthly 
dose of allergen proteins was 119.4  μg, while the mean 
cumulative dose per year was about 1.4 mg.
Patients from both groups (irrespective to SLIT) 
received an appropriate pharmacological treatment 
according to ARIA and GINA guidelines depending on 
symptoms: oral antihistamines, intranasal corticosteroid, 
inhaled corticosteroid and inhaled bronchodilator.
Clinical evaluation
All patients were followed up during the 2 years from the 
beginning of the protocol. Patients were asked to fill in 
the symptom and medication score diary on a daily base 
twice a day (in the morning and in the evening) during 
1-month period or during the pollen season for patients 
who were sensitized to seasonal allergens. Older children 
were also asked to calculate the mean values, usually with 
parents help.
The following symptoms of AR were scored: rhinor-
rhea, sneezing, nasal itching and blocked nose. In addi-
tion, for the AR with AA patients, next symptoms were 
scored: chest tightness, shortness of breath, cough and 
wheezing. Each symptom was scored as 0 (absent), 1 
(mild), 2 (moderate), 3 (severe) and the mean monthly 
symptom score (SS) was calculated. The use of sympto-
matic medications was also recorded daily, during the 
same period. Anti-allergic medication requirement was 
evaluated as the monthly mean medication score (MS). 
Airways eosinophilic inflammation measurement was 
performed with NIOX MINO (Aerocrine, Solna, Swe-
den). The data were interpreted according to the recom-
mendations of American Thoracic Society (ATS) [14–17] 
(Table 1). Conditions potentially influencing FeNO values 
(anxiety, cardiac disease, chronic obtrusive disease, 
GERB, non eosionophilic asthma, rhinosinusitis, voice 
cord dysfunction, cyctic fibrosis, primary ciliary dyskine-
sia infection and asthma exacerbation) were excluded.
Lung function test was performed at each visit using 
Jaeger, Pneumo Screen spirometry. Subjects were advised 
to avoid the use of the short-acting bronchodilator at 
least 12 h before the test. FEV1 values were expressed as 
a percentage of predicted values.
The patients receiving SLIT were required to record 
and give their report on a specific diary card, in the 
case of side effects: local (oral itching/burning, swell-
ing, oedema of the uvula or tongue) or systemic adverse 
reactions (asthma, rhinitis, urticaria, angioedema, gen-
eralized itching, gastrointestinal symptoms—abdominal 
pain, nausea, vomiting, shock).
Statistical analysis
The sample size was calculated with the software pack-
age G power. A sufficient number of observation units for 
the error level α = 0.05 and power of the study 1−β = 0.8 
is 0.72 were considered. Descriptive and analytical sta-
tistical methods were used. The following descriptive 
variables were described: measures of central tendency 
(mean, median), measure of dispersion (standard devia-
tion, interval of variation). Analytical statistical methods 
were used to test differences, parametric and nonpara-
metric variables. Student’s t test and analysis of vari-
ance of repeated measurements were used. Chi square 
test, McNemar test, Mann–Whitney test, Wilcoxon test, 
Friedman test were also included. All data were analyzed 
in SPSS 15.0 software package. (SPSS Inc., Chicago, Illi-
nois, USA).
Results
Overall 59 patients (mean age, 13.18  ±  3.433 range 
7–20  years; 50.8% boys; 49.2% girls) were included: 34 
(20 girls and 14 boys) received SLIT as an add-on to drug 
therapy and 25 (10 girls and 15 boys) received anti-aller-
gic and asthmatic drug therapy alone. Patients from SLIT 
and control group were homogenous for all demographic 
and clinical characteristics.
We found clinical improvement in the SLIT group, 
demonstrated by statistically significant decrease of all 
rhinitis symptoms after 2  years of SLIT vs. baseline for 
both groups (Table 2).
According to our statistical analysis 75% of patients 
on SLIT didn’t complain about nasal congestion after 
2  years of treatment; 80% of the patients in the same 
group didn’t have nasal pruritus, whereas SLIT was effec-
tive in treating rhinorrhea and sneezing in 75% patients. 
On the other side standard pharmacotherapy didn’t have 
such a significant impact on nasal symptoms. We also 
Table 1 FeNO interpretation




Control asthma <25 <20
Intermediate 25–30 25–30
Non‑control asthma >50 >35
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found a statistically significant inter-group difference for 
all rhinitis symptom scores, after 1st year with a further 
improvement of symptoms in the group on SLIT during 
the 2nd year of follow up period.
A similar clinical improvement SLIT expressed on 
asthma symptom scores. Our results demonstrated 
decrease of all asthma symptom scores during the fol-
low up period for all participants with a statistical sig-
nificant influence of SLIT group on that improvement. 
The results are showed in Table 3. After 2 years of SLIT 
treatment more than 80% of the patients didn’t com-
plain about cough, night cough, and chest breathless and 
wheezing. We also found a statistically significant inter-
group difference for all asthma symptom scores, after 
1st year with a further improvement of symptoms in the 
group on SLIT during the 2nd year of follow up period. 
All data are summarized in Table 4.
χ2 test showed statistical significant differences for all 
rhinitis and asthma scores in all of three periods. At the 
beginning of the follow up period children in SLIT group 
had more severe symptoms in comparison with children 
on standard pharmacotherapy. Even after a 1-year follow 
up we, a significant improvement was registered. Similar 
results were observed at 2nd year, especially for patients 
with more severe symptoms.
The data from our study showed that after 2 years the 
use of inhaled corticosteroids, intranasal corticoster-
oids, β2 agonists was significantly reduced in the group 
of patients on SLIT (Z = − 4311 p < 0.001, χ2 = 30,785; 
p  <  0.001, Q =  28,783; p  <  0.001 respectively), in com-
parison with the control group (Fig.  2). The patients in 
the experimental group also used statistically less anti-
histamines (χ2  =  32,774; p  <  0.001) and leukotrienes 
(*χ2 = 30,785; p < 0.001) in comparison with the patients 
in non-SLIT group, but only after 2 years of AIT.
Although at the beginning of the study all patients had 
FEV1  ≥80% of predicted value, SLIT showed a signifi-
cant improvement of FEV1 just after 1  year with a fur-
ther improvement in the 2nd  year of follow up period 
(F  =  3514; p  =  0.036), while at the same time FEV1 
remain without any improvement in children on stand-
ard pharmacotherapy (F = 3199; p = 0.048) (Fig. 3).
The level of FeNO decreased significantly in all the three 
measurements during SLIT course (χ2 = 52,220; p < 0.001). 
During the follow up period significant differences between 
the groups in all three measurements were observed. 
Patients in the experimental group had significantly higher 
values of FeNO in all measurements. When we compared 
the values in each group independently, we found only sig-
nificant reduction in the experimental group. We observed 
both significant reduction between FeNO1 and FeNO2 
(p  <  0.001) and between FeNO2 and FeNO3. Through-
out the treatment period there was a sustained significant 
reduction between FeNO2 and FeNO3. Max value for 
FeNO1 was 111 ppb, while MaxFeNO2 and FeNO3 were 
78 and 56  ppb consecutively. Here we showed that there 
is an influence of SLIT on the FeNO values in children in 
experimental group, whereas no reduction in FeNO values 
were registered in the control group (Table 5, Fig. 4).
Table 2 The distribution of  values for  a patient rhinitis 
symptom scores
Nasal congestion χ2 = 37,783; p < 0.001
Nasal pruritus χ2 = 38,346; p < 0.001
Rhinorrhea χ2 = 42,012; p < 0.001
Sneezing χ2 = 44,831; p < 0.001
Table 3 The distribution of  values for  asthma symptom 
scores
Cough χ2 = 62,384; p < 0.001
Night cough χ2 = 47,743; p < 0.001
Chest breathless χ2 = 49,622; p < 0.001
Wheezing χ2 = 49,078; p < 0.001
Table 4 χ2 test symptoms scores during SLIT course




Nasal congestion 10,299 8732 10,835
Nasal pruritus 5601 8877 8737
Rhinorrhea 8119 10,001 12,464
Sneezing 6407 10,605 9821
Cough 8100 5322 16,028
Night cough 9114 5177 12,666
Chest breathless 5656 2154 9680







Fig. 2 The usage of β2 agonists
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Safety assessment
There were no local side effects that required treatment. 
Three side effects were reported. All of them involved mild 
to moderate gastrointestinal complaints (mouth burning 
or itching and stomachache and nausea) and self- resolve 
in a few days without any intervention. It is noteworthy 
that no serious adverse events were reported in the pre-
sent survey, and the incidence of side-effects appeared to 
be lower than that reported for injective immunotherapy.
Discussion
This is one of the first studies evaluating clinical efficacy, 
pulmonary function, FeNO and safety in children with 
both allergic rhinitis and asthma undergoing SLIT or 
drug treatment. In the current study we found: (a) sta-
tistically significant improvement in nasal and asthma 
symptom scores after 1 year of treatment in SLIT group, 
with further improvement in the 2nd  year of follow up 
(75 and 80% respectively) compared with control group; 
(b) only three patients reported mild local and systemic 
adverse reactions; (c) statistically significant improve-
ment of pulmonary function; (d) statistically significant 
decrease of eosinophilic inflammation of lower airways 
measured with FeNO. Since SLIT was first introduced 
for treatment of respiratory allergies in children and 
later accepted as a viable alternative to SCIT, need for an 
assessment of its efficacy and safety in respiratory allergy 
has emerged [18]. Consequently, many randomized dou-
ble blind placebo controlled and open controlled tri-
als [19–27], as well as a number of systematic reviews 
and meta-analyses have been carried out to determine 
the efficacy and safety of SLIT [28–36]. Data from lit-
erature suggested overall clinical effectiveness of SLIT in 
patients with AR and AA, although the conclusions were 
restricted by heterogeneity of the studies, especially con-
cerning the manufacturer’s variability of allergen content 
in commercial extracts. In our study the only available 
SLIT extracts in Serbia was used, and the exact dose in 
micrograms of major allergen was calculated.
The comparison between immunotherapy and 
standard pharmacological treatment is still a matter of 
debate. Clinical effects of SLIT can be appreciated only 
in the long term period (months), whereas traditional 
drugs act immediately. Data from literature showed 
that efficacy of SLIT is dose-dependent and sufficient 
duration of treatment is essential to elicit the immu-
nologic changes underlying its clinical effectiveness. 
According to our results, SLIT seems to be a beneficial 
Fig. 3 Respiratory function
Table 5 The level of FeNO (Legend FeNO I baseline. FeNO II–1st year of follow-up period, FeNO III-2nd year of follow-up 
period)
N Mean value SD Median Minimum Maximum
No 1 34 60.65 20.467 56.00 31 111
No 2 34 43.18 8.990 43.00 31 78
No 3 34 34.15 6.985 32.00 22 56
Fig. 4 The level of FeNO
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therapeutic strategy. In our study, after 12  months of 
treatment, reduction in all clinical scores was observed 
in the SLIT group (in up to 75% of the patients). 
Reduction of drug intake indicates that pharmacologi-
cal treatment does not prime SLIT efficacy. Compari-
son between groups showed statistically significant 
reduction of drug scores and symptoms scores in SLIT 
group.
Exhaled NO has been shown to reflect the levels of air-
way inflammation in asthmatic patients [37, 38]. In addi-
tion, it has also been reported that asthmatic patients 
show higher levels of NO in peripheral blood and that 
serum levels can be used as an additional inflammatory 
marker in asthma [39]. No study has yet investigated the 
effect of AIT on NO concentration, although AIT with 
D. pteronyssinus and D. farinae extracts has been found 
to reduce exhaled NO in asthmatic children with mite 
allergy [40]. However the results from the studies are 
controversial and a clear demonstration of a reduction 
in exhaled NO in asthmatic patients taking SLIT is lack-
ing [41]. According to our data NO levels decreased after 
SLIT, possibly reflecting a reduction in systemic allergic 
inflammation.
Some potential limitations of our study have to be 
pointed out. Patients were not stratified according to 
sensitizations, which could have an impact on SLIT effec-
tiveness and results of clinical scores. The small study 
population sample did not allow a proper subanalysis 
by sensitization profile. Furthermore the quality of SLIT 
extract is questionable, but the extract we used is the only 
available product in Serbian market.
Conclusions
Our data showed that SLITOR is an effective treatment, 
decreasing both symptom and medication scores in the 
active group. These findings suggest that SLIT may have 
preventive effects, showing in children with intermittent 
asthma and AR a lower occurrence of persistent airway 
inflammation. Combining clinical outcomes with respira-
tory function and FeNO values, we could be able to phe-
notype the most adequate patients who will benefit from 
SLIT. When evaluating the effect of AIT, it is appropriate 
to consider results affecting both the upper and the lower 
airways, whereas measurement of FeNO is of a great 
importance.
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